Literature DB >> 16876120

Sp1 mediates repression of the resistin gene by PPARgamma agonists in 3T3-L1 adipocytes.

S S Chung1, H H Choi, Y M Cho, H K Lee, K S Park.   

Abstract

Resistin is an adipokine related to obesity and insulin resistance. Expression of the resistin gene is repressed by the treatment of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists, thiazolidinediones (TZDs). In this study, we investigated the mechanism by which TZDs inhibit the resistin gene expression. Resistin gene expression was decreased by TZD in fully differentiated 3T3-L1 adipocytes, which was abolished after treatment of cycloheximide (a protein synthesis inhibitor). TZD could not repress the expression of the resistin gene in the presence of mithramycin A (an Sp1 binding inhibitor). Sp1 binding site of the resistin promoter (-122/-114bp) was necessary for the repression. Further investigation of the effect of TZDs on the modification of Sp1 showed that the level of O-glycosylation of Sp1 was decreased in this process. These results suggest that PPARgamma activation represses the expression of the resistin gene by modulating Sp1 activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876120     DOI: 10.1016/j.bbrc.2006.07.048

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Study of Resistin gene expression in peripheral blood mononuclear cell and its gene polymorphism in a small range population.

Authors:  Yun-mei Yang; Zhe-rong Xu; Ling-jiao Wu; Wei-dong Huang
Journal:  J Zhejiang Univ Sci B       Date:  2007-02       Impact factor: 3.066

2.  SP1 suppresses phorbol 12-myristate 13-acetate induced up-regulation of human regucalcin expression in liver cancer cells.

Authors:  Hong Xu; Peihua Ni; Changqiang Chen; Yuting Yao; Xiaoping Zhao; Guanxiang Qian; Xianqun Fan; Shengfang Ge
Journal:  Mol Cell Biochem       Date:  2011-04-28       Impact factor: 3.396

3.  Transcription of human resistin gene involves an interaction of Sp1 with peroxisome proliferator-activating receptor gamma (PPARgamma).

Authors:  Anil K Singh; Aruna Battu; Krishnaveni Mohareer; Seyed E Hasnain; Nasreen Z Ehtesham
Journal:  PLoS One       Date:  2010-03-29       Impact factor: 3.240

4.  Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice.

Authors:  Timothy D Wiggin; Matthias Kretzler; Subramaniam Pennathur; Kelli A Sullivan; Frank C Brosius; Eva L Feldman
Journal:  Endocrinology       Date:  2008-06-26       Impact factor: 4.736

5.  Hexosamine biosynthesis impairs insulin action via a cholesterolgenic response.

Authors:  Brent A Penque; April M Hoggatt; B Paul Herring; Jeffrey S Elmendorf
Journal:  Mol Endocrinol       Date:  2013-01-11

6.  Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.

Authors:  Brian M Necela; Weidong Su; E Aubrey Thompson
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

7.  Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding proteins.

Authors:  Takuya Tomaru; David J Steger; Martina I Lefterova; Michael Schupp; Mitchell A Lazar
Journal:  J Biol Chem       Date:  2009-01-05       Impact factor: 5.157

Review 8.  Role of transcription factor modifications in the pathogenesis of insulin resistance.

Authors:  Mi-Young Kim; Jin-Sik Bae; Tae-Hyun Kim; Joo-Man Park; Yong Ho Ahn
Journal:  Exp Diabetes Res       Date:  2011-10-26

9.  Liganded peroxisome proliferator-activated receptors (PPARs) preserve nuclear histone deacetylase 5 levels in endothelin-treated Sprague-Dawley rat cardiac myocytes.

Authors:  Haining Zhang; Zongjun Shao; Caroline P Alibin; Crystal Acosta; Hope D Anderson
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

10.  The Role of PPARs in Lung Fibrosis.

Authors:  Heather F Lakatos; Thomas H Thatcher; R Matthew Kottmann; Tatiana M Garcia; Richard P Phipps; Patricia J Sime
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.